A Phase 2 interventional study of dabigatran in Venous Thromboembolism, sponsored by Boehringer Ingelheim. Completed at 4 sites in 3 countries. Open to participants aged Up to 12 Months. Per ClinicalTrials.gov, last updated 2016-09-20.
Sponsored by Boehringer Ingelheim · Phase 2 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing dabigatran in Venous Thromboembolism — 1 open to participants now, 1 under way, none of them phase 3. Dabigatran · Venous Thromboembolism.
Among the 17 studies testing dabigatran in Venous Thromboembolism, this one is the 16th largest by enrollment, is one of 2 that started in 2014, is one of 7 in phase 2, and was the 14th registered.
713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.
Browse Venous Thromboembolism studies →1 of the 17 studies testing dabigatran in Venous Thromboembolism is open now, in 1 country. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: Up to 12 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 241 across 402 interventional studies indexed under Venous Thromboembolism.
Median enrollment 148 across the 17 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 6 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
17 studies in Venous Thromboembolism by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 15 finished, 13 (87%) have results posted.
Among the 17 studies in Venous Thromboembolism by Boehringer Ingelheim, this one is the 11th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2014, is one of 7 in phase 2, and was the 14th registered.
Boehringer Ingelheim’s Venous Thromboembolism studies by the year they started, since 2000.
1 of the studies testing dabigatran in Venous Thromboembolism that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05735639Imperial College LondonTHRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing dabigatran in Venous Thromboembolism, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 17 in Venous Thromboembolism:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of the study is to investigate the safety and tolerability of dabigatran etexilate solution in children aged less than 1 year, to demonstrate comparable PK/PD relationship to older children and adults and to confirm dabigatran etexilate dosing algorithm for children aged less than 1 year.
Purpose:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
open label arm with dabigatran oral liquid formulation as single dose
Drug: dabigatran
Experimental dose chosen based on age and weight
Plasma Concentrations of Total Dabigatran, 2h and 12 h (+/-2h) Post Administration of Dabigatran Etexilate
Plasma concentrations of total dabigatran, 2h and 12 h (+/-2h) post administration of dabigatran etexilate.
Time frame: 2 hours (h) and 12h after drug administration on day 1
Central Measurement: The Mean aPTT Coagulation Time at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.
Central measurement: The mean activated partial thromboplastin time (aPTT) coagulation time at 2 h and 12 h (±2 h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation.
Time frame: 2 h, and 12 h after dosing on day 1
Central Measurement: The Mean of ECT Coagulation Time at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.
Central measurement: The mean of Ecarin Clotting Time (ECT) coagulation time at 2 h and 12h (+/-2h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation.
Time frame: 2 h, and 12 h after dosing on day 1
Central Measurement: The Mean of Diluted Thrombin Time (dTT) Coagulation Time at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.
Central measurement: The mean of dTT (AntiFactor IIa activity) coagulation time at 2 h and 12h (+/-2h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation.
Time frame: 2 h, and 12 h after dosing on day 1
Central Measurement: The Mean aPTT Ratio at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.
Central measurement: The mean aPTT (activated partial thromboplastin time) ratio at 2 h and 12 h (±2 h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation. aPTT ratio= aPTT (post dose)/aPTT (baseline). The mean of aPTT ratio is presented.
Time frame: baseline (0.5 h before intake of study medication), 2 h, and 12 h after dosing on day 1
Central Measurement: The Mean ECT Ratio at 2 h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.
Central measurement: The mean Ecarin Clotting Time (ECT) ratio at 2 h and 12h (+/-2h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation. ECT ratio= ECT(Post dose)/ECT(baseline), The mean of ECT ratio is presented.
Time frame: baseline (0.5 h before intake of study medication), 2 h, and 12 h after dosing on day 1
Central Measurement: The Mean of dTT Ratio at 2h and 12h (+/-2h) Post Administration of Dabigatran Etexilate.
Central measurement: The mean of dTT (AntiFactor IIa activity) ratio at 2 h and 12 h (±2 h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation. dTT ratio= dTT(post dose)/dTT(baseline). The mean of dTT ratio is presented.
Time frame: baseline (0.5 h before intake of study medication), 2 h, and 12 h after dosing on day 1
PK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters APTT Values.
Linear regression models were used for modeling the relationship between total dabigatran plasma concentration and coagulation parameters APTT values. For our simple regression model, R-squared is equal to the square of Pearson's coefficient of correlation. The R-squared can be between 0 and 1. R-squared =1 means a perfect fit.
Time frame: baseline (0.5 h before intake of study medication), 2 h, and 12 h after dosing on day 1
PK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters ECT Values.
Linear regression models were used for modeling the relationship between total dabigatran plasma concentration and coagulation parameters ECT values. For our simple regression model, R-squared is equal to the square of Pearson's coefficient of correlation. The R-squared can be between 0 and 1. R-squared =1 means a perfect fit.
Time frame: baseline (0.5 h before intake of study medication), 2 h, and 12 h after dosing on day 1
PK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters dTT Values.
Linear regression models were used for modeling the relationship between total dabigatran plasma concentration and coagulation parameters dTT (AntiFactor IIa activity) values. For our simple regression model, R-squared is equal to the square of Pearson's coefficient of correlation. The R-squared can be between 0 and 1. R-squared =1 means a perfect fit.
Time frame: baseline (0.5 h before intake of study medication), 2 h, and 12 h after dosing on day 1
Incidence of All Bleeding Events (Major, CRNM and Minor) During the Treatment Period.
Percentage of patients with Incidence of all bleeding events(major, clinically relevant non-major (CRNM) \& minor) during the treatment period (including the residual effect period).Bleeding events were classified as follow: Major bleeding: 1) Fatal bleeding 2) Clinically overt bleeding associated with decrease in haemoglobin of at least 2 g/dL (20 g/L) in 24-h-period 3) Bleeding that was retroperitoneal, pulmonary, intracranial, or otherwise involved the central nervous system 4) Bleeding that required surgical intervention in an operating suite. CRNM bleeding: 1) Overt bleeding for which a blood product was administered \& which was not directly attributable to the patient's underlying medical condition 2) Bleeding that required medical or surgical intervention to restore haemostasis, other than in an operating suite. Minor bleeding defined as any overt or macroscopic evidence of bleeding that did not fulfil the criteria for either major bleeding or CRNM bleeding.
Time frame: Within two days after the administration of trial medication, up to 3 days
Incidence of All AEs During the Treatment Period
Percentage of patients with all adverse events (AEs) during the treatment period (including REP).
Time frame: Within two days after the administration of trial medication, up to 3 days
Global Assessment of Acceptability and Tolerability of Study Medication
The investigator was to provide a global clinical assessment of tolerability and acceptability of study medication by the patient.This assessment was based on 5-point scale (good, satisfactory, not satisfactory, bad, not assessable).
Time frame: Day 1 (immediately after dosing)
| Milestone | Dabigatran Etexilate |
|---|---|
| Started | 8 |
| Completed | 8 |
| Not completed | 0 |
Plasma concentrations of total dabigatran, 2h and 12 h (+/-2h) post administration of dabigatran etexilate.
| ng/mL | Dabigatran Etexilate |
|---|---|
| 2h | 120.0 ± 62.1 |
| 12h | 60.4 ± 30.0 |
Central measurement: The mean activated partial thromboplastin time (aPTT) coagulation time at 2 h and 12 h (±2 h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation.
| second | Dabigatran Etexilate |
|---|---|
| E2 | 78.9 ± 26.7 |
| E12 | 62.8 ± 27.7 |
Central measurement: The mean of Ecarin Clotting Time (ECT) coagulation time at 2 h and 12h (+/-2h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation.
| second | Dabigatran Etexilate |
|---|---|
| E2 | 101 ± 44.3 |
| E12 | 66.9 ± 23.5 |
Central measurement: The mean of dTT (AntiFactor IIa activity) coagulation time at 2 h and 12h (+/-2h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation.
| second | Dabigatran Etexilate |
|---|---|
| E2 | 48.7 ± 24 |
| E12 | 38.6 ± 8.12 |
Central measurement: The mean aPTT (activated partial thromboplastin time) ratio at 2 h and 12 h (±2 h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation. aPTT ratio= aPTT (post dose)/aPTT (baseline). The mean of aPTT ratio is presented.
| ratio | Dabigatran Etexilate |
|---|---|
| ER2 | 1.86 ± 19.5 |
| ER12 | 1.47 ± 17.7 |
Central measurement: The mean Ecarin Clotting Time (ECT) ratio at 2 h and 12h (+/-2h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation. ECT ratio= ECT(Post dose)/ECT(baseline), The mean of ECT ratio is presented.
| Ratio | Dabigatran Etexilate |
|---|---|
| ER2 | 2.42 ± 34.2 |
| ER12 | 1.63 ± 13.8 |
Central measurement: The mean of dTT (AntiFactor IIa activity) ratio at 2 h and 12 h (±2 h) post administration of dabigatran etexilate. Standard deviation is actually the Coefficient of Variation. dTT ratio= dTT(post dose)/dTT(baseline). The mean of dTT ratio is presented.
| ratio | Dabigatran Etexilate |
|---|---|
| ER2 | 1.59 ± 25.4 |
| ER12 | 1.26 ± 5.67 |
Linear regression models were used for modeling the relationship between total dabigatran plasma concentration and coagulation parameters APTT values. For our simple regression model, R-squared is equal to the square of Pearson's coefficient of correlation. The R-squared can be between 0 and 1. R-squared =1 means a perfect fit.
| R-Square | Dabigatran Etexilate |
|---|---|
| PK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters APTT Values. | 0.752 |
Linear regression models were used for modeling the relationship between total dabigatran plasma concentration and coagulation parameters ECT values. For our simple regression model, R-squared is equal to the square of Pearson's coefficient of correlation. The R-squared can be between 0 and 1. R-squared =1 means a perfect fit.
| R-Square | Dabigatran Etexilate |
|---|---|
| PK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters ECT Values. | 0.858 |
Linear regression models were used for modeling the relationship between total dabigatran plasma concentration and coagulation parameters dTT (AntiFactor IIa activity) values. For our simple regression model, R-squared is equal to the square of Pearson's coefficient of correlation. The R-squared can be between 0 and 1. R-squared =1 means a perfect fit.
| R-Square | Dabigatran Etexilate |
|---|---|
| PK-PD Relationship: Relationship Between Total Dabigatran Plasma Concentration and Coagulation Parameters dTT Values. | 0.920 |
Percentage of patients with Incidence of all bleeding events(major, clinically relevant non-major (CRNM) \& minor) during the treatment period (including the residual effect period).Bleeding events were classified as follow: Major bleeding: 1) Fatal bleeding 2) Clinically overt bleeding associated with decrease in haemoglobin of at least 2 g/dL (20 g/L) in 24-h-period 3) Bleeding that was retroperitoneal, pulmonary, intracranial, or otherwise involved the central nervous system 4) Bleeding that required surgical intervention in an operating suite. CRNM bleeding: 1) Overt bleeding for which a blood product was administered \& which was not directly attributable to the patient's underlying medical condition 2) Bleeding that required medical or surgical intervention to restore haemostasis, other than in an operating suite. Minor bleeding defined as any overt or macroscopic evidence of bleeding that did not fulfil the criteria for either major bleeding or CRNM bleeding.
| Percentage of participants | Dabigatran Etexilate |
|---|---|
| Incidence of All Bleeding Events (Major, CRNM and Minor) During the Treatment Period. | 0.0 |
Percentage of patients with all adverse events (AEs) during the treatment period (including REP).
| percentage of participants | Dabigatran Etexilate |
|---|---|
| Incidence of All AEs During the Treatment Period | 0.0 |
The investigator was to provide a global clinical assessment of tolerability and acceptability of study medication by the patient.This assessment was based on 5-point scale (good, satisfactory, not satisfactory, bad, not assessable).
| percentage of participants | Dabigatran Etexilate |
|---|---|
| Good | 75.0 |
| Satisfactory | 12.5 |
| Not satisfactory | 0.0 |
| Bad | 12.5 |
| Not assessable | 0.0 |
Collected over Within two days after the administration of trial medication, up to 3 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dabigatran Etexilate | — | 0/8 (0%) | 0/8 (0%) |
Treated set (TS): the treated set included 8 patients who were dispensed study medication and were documented to have taken at least 1 dose of trial medication.
| Age, Continuous(Months) | Dabigatran Etexilate |
|---|---|
| Mean | 2.912 ± 1.694 |
| Sex: Female, Male(Participants) | Dabigatran Etexilate |
|---|---|
| Female | 5 |
| Male | 3 |
The record gives a start of Sep 2014, a primary completion of Jan 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2016, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dabigatran